Interview: Wendy Adams – General Manager, Galderma Canada
Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing…
Galderma is a leading global pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, therapeutic skin care and aesthetic and corrective medical solutions) contribute to maintaining its strong leadership in dermatology. Galderma is committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 31 wholly-owned affiliates with a worldwide network of distributors and more than 4,000 employees.
Galderma Canada Inc. offers a product portfolio to treat a range of dermatological conditions including: acne, eczema, rosacea, psoriasis and non-melanoma skin cancer.
Strategic brands include:
Tactuo® and Differin® (acne), MetroGel® and Apprilon™ (rosacea), Clobex® (psoriasis), Metvix® (skin cancer), Cetaphil® (therapeutic skin care)
Wendy Adams, general manager of Galderma Canada, outlines the main achievements of the affiliate since 2013, the best practices she can share with Galderma globally when it comes to managing…
Jim Keon, President of the CGPA, discusses how the Canadian generics industry is adapting to the current period of political transition and how it engages in talks with the government…
Jonathan Ross Goodman, founder and CEO of Knight Therapeutics Inc., discusses the unique backstory behind the founding of the company, coming on the heels of the sale of Paladin Labs…
Luc Boileau, president and CEO of INESSS, the Quebecois National Institute of Excellence in Health and Social Services, the region’s healthcare technology assessment (HTA) body, describes how his organization is…
Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of…
Professor Rémi Quirion, chief scientist of Québec, discusses his mandate, encourages interprovincial collaboration between Ontario and Québec in the life sciences sector and explains the importance of engaging with civil…
Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed…
Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends…
Dr. Gaétan Barrette, Minister of Health and Social Services for Quebec, recaps the ambitious healthcare reforms pertaining to system integration and primary care access he has implemented since assuming position…
Pamela C. Fralick, President of Innovative Medicines Canada (IMC), the innovative pharma association in Canada, looks back on her first half year in position, the challenges of navigating Canada’s complex…
Therapure President and CEO, Nick Green, speaks about the environment for contract development and manufacturing in Canada and the integrated services that Therapure can offer its global customers as a…
Canada operates a single-payer healthcare system in which the majority of services are provided by private entities, which are paid for at the provincial level. The Canada Health Act…
The CEO of DelMar Pharmaceuticals discusses British Columbia’s competitive strengths in the biotechnology space, and demonstrates how his company’s therapy for glioblastoma will change the way in which a number…
See our Cookie Privacy Policy Here
